Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Sophie Park; Jean-François Hamel; Andrea Toma; Charikleia Kelaidi; Sylvain Thépot; Maria Díez Campelo; Valeria Santini; Mikkael A Sekeres; Rami Komrokji; David Steensma; Enrico Balleari; Katharina S Götze; Ioannis Kotsianidis; Agnès Guerci-Bresler; Aspasia Stamatoullas; Guillermo F Sanz; Ulrich Germing; Pierre Fenaux

doi:10.1016/j.leukres.2020.106472

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Leuk Res. 2020 Dec:99:106472. doi: 10.1016/j.leukres.2020.106472. Epub 2020 Nov 5.

Authors

Sophie Park¹, Jean-François Hamel², Andrea Toma³, Charikleia Kelaidi⁴, Sylvain Thépot⁵, Maria Díez Campelo⁶, Valeria Santini⁷, Mikkael A Sekeres⁸, Rami Komrokji⁹, David Steensma¹⁰, Enrico Balleari¹¹, Katharina S Götze¹², Ioannis Kotsianidis¹³, Agnès Guerci-Bresler¹⁴, Aspasia Stamatoullas¹⁵, Guillermo F Sanz⁶, Ulrich Germing¹⁶, Pierre Fenaux¹⁷

Affiliations

¹ Centre hospitalo-universitaire (CHU) Grenoble Alpes, Service d'hématologie, Université Grenoble Alpes, INSERM U1209, Institute for Advanced Biosciences, UMR CNRS 5309, CS 10217, 38043, GRENOBLE Cedex 09, France. Electronic address: spark@chu-grenoble.fr.
² CHU d'Angers, Angers, France.
³ Hôpitaux Universitaires Henri Mondor, Hematologie-DMU Gériatrie, Assistance Publique Hopitaux de Paris (AP-HP), Paris, France.
⁴ Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece.
⁵ CHU Angers, Université d'Angers, Inserm, Unité 1232, LabEx IGO, Angers, France.
⁶ Hospital Universitario de Salamanca, Salamanca, GESMD, Spain.
⁷ Hematology Unit-AOU Careggi, University of Florence, Firenze, Italy.
⁸ Division of Hematology, Sylvester Comprehensive cancer Center, University of Miami, Miami, Florida, USA.
⁹ H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
¹⁰ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
¹¹ Medicina Interna, Ospedale Imperia ASL1, Imperiese via s. Agata, 57 docente Dottorato Ematologia Oncologia e Medicina Interna Clinico-Traslazionale Università di Genova, Italy.
¹² Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, München, Germany.
¹³ Democritus University of Thrace, University Hospital of Alexandroupolis, Department of Hematology, Alexandroupolis, Greece.
¹⁴ CHU de Nancy, France.
¹⁵ Centre Henri Becquerel (CHB), Rouen, France.
¹⁶ Heinrich-Heine University Dusseldorf, Universitätsklinikum, Dept. of Hematology, Oncology and Clinical Immunology, Dusseldorf, Germany.
¹⁷ Hôpital Saint Louis, APHP, and Université de Paris, France.

PMID: 33212326
DOI: 10.1016/j.leukres.2020.106472

No abstract available

Publication types

Letter

MeSH terms

Activin Receptors, Type II / therapeutic use
Aged
Anemia, Sideroblastic / drug therapy*
Anemia, Sideroblastic / mortality
Anemia, Sideroblastic / therapy
Azacitidine / therapeutic use
Disease Progression
Erythrocyte Transfusion
Erythropoietin / blood
Female
Ferritins / blood
Follow-Up Studies
Hematinics / therapeutic use*
Humans
Immunoglobulin Fc Fragments / therapeutic use
Kaplan-Meier Estimate
Lenalidomide / therapeutic use
Male
Proportional Hazards Models
Recombinant Fusion Proteins / therapeutic use
Salvage Therapy*
Treatment Failure

Substances

EPO protein, human
Hematinics
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins
Erythropoietin
Ferritins
luspatercept
Activin Receptors, Type II
Lenalidomide
Azacitidine